Page 102 - HIV/AIDS Guidelines

resistance-associated mutations to this drug. J Antimicrob Chemother. 2009;64(5):1087-1090.

31. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with
delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS
Clinical Trials Group Study 359. J Infect Dis. 2000;182(5):1375-1384.
32. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment
failure: a randomized trial. JAMA. 2002;288(2):169-180.
33. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised
background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the
Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an
analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534):466-475.
34. Murray JS, Elashoff MR, Iacono-Connors LC, et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of
antiretroviral drugs. AIDS. 1999;13(7):797-804.
35. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected
patients with treatment failure. AIDS. 2000;14(18):2857-2867.
36. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among
HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51-62.
37. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV
therapy. J Acquir Immune Defic Syndr. 2004;37(1):1147-1154.

38. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination
antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344(7):472-480.

39. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human
immunodeficiency virus. N Engl J Med. 2003;349(9):837-846.

40. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive
HIV-1 infected adults. AIDS. 2001;15(11):1369-1377.

41. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons
with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441-446.
42. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection
receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163(18):2187-
2195.
43. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according
to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36(2):702-713.
44. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of
potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(2):168-175.
45. Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and
CD4 cell count increases in patients with suppressed viremia. AIDS. 2006;20(8):1141-1150.
46. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among
3
individuals enrolling into care with CD4+ counts greater than 200 cells/mm . J Acquir Immune Defic Syndr.
2007;44(2):179-187.

47. Loutfy MR, Walmsley SL, Mullin CM, et al. CD4(+) cell count increase predicts clinical benefits in patients with
advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis.
2005;192(8):1407-1411.
48. Moore DM, Hogg RS, Chan K, et al. Disease progression in patients with virological suppression in response to HAART
is associated with the degree of immunological response. AIDS. 2006;20(3):371-377.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents H-9

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.